Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

Talk about confidence that their novel drugs are working to benefit patients - MNTA has established a new section on their web site as of 11 February 2019 -

Early/Expanded Access Policy

Momenta is committed to developing safe and effective medicines to treat rare immune-mediated diseases with high unmet medical needs. Our goal is to ensure access to our investigational drug, at the appropriate time and in a clinically appropriate manner for patients.

Momenta’s Early/Expanded Access Policy (EAP) refers to the use of an investigational drug outside of a clinical trial. This is initiated when the primary purpose is to diagnose, prevent, or treat a serious condition in a patient, which is different from a clinical trial where more comprehensive safety and efficacy data are collected. At Momenta, we recognize and understand the need for an early/expanded access policy.

A number of factors consistent with the US Food and Drug Administration (FDA) and other regulatory agencies' guidelines should be taken into account when considering this kind of access.

Read more:
Momenta’s Key Eligibility Requirements, etc. -

http://www.momentapharma.com/pipeline/expanded-access-policy.php